INS and type 1 diabetes mellitus: While stratifying patients based on their endotype and disease stage (“who and when”) could provide more personalized therapeutic options, this also highlights the crucial need for better biomarkers of T1D progression and response to immunotherapy, as current outcome measures for clinical trials are largely limited to metabolic (i.e., C-peptide preservation) and clinical criteria (i.e., insulin needs and glycemic control).